To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.

Medical practitioners are constantly updating and refining approaches to prostate cancer care, while new cutting-edge ...

A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly ...

An update in the New England Journal of Medicine has shown that transcatheter arterialization of the deep veins (TADV) using ...

Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not ...

Researchers have found in a large randomized trial that men with metastatic prostate cancer receiving androgen deprivation ...

By Dr Mihir Shanker, Radiation Oncologist, Icon Cancer CentreFor many men, a prostate cancer diagnosis raises understandable ...

The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.

Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...

Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Study Overview: Boston Scientific is conducting a study titled ...

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...